New drug cocktail aims to stop bile duct cancer from coming back
NCT ID NCT04669496
First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 22 times
Summary
This study tests whether giving a combination of immunotherapy (Toripalimab), a targeted drug (Lenvatinib), and chemotherapy (GEMOX) before surgery can improve outcomes for people with a high-risk type of bile duct cancer. About 178 participants will be randomly assigned to receive either the drug combo followed by surgery, or surgery alone. The main goal is to see if the combo delays cancer return or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan hospital
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.